Fibromyalgia is a never-ending, health circumstance that is best described by defining its symptoms. These include, but certainly are not limited to: all-over body pain in the muscles, ligaments and tendons; numerous sore-to-the-touch areas on the body, or tender points, where even the slightest strain causes immense pain and recurrent tiredness even after lengthy sleep. The indications of Fibromyalgia can vary according to the time of day, weather, stress and/or physical activity. There are no medical tests for Fibromyalgia. Doctors must first rule out all other conditions that could be causing these symptoms before diagnosing a patient with Fibromyalgia.

Experts theorize that people with Fibromyalgia never truly reach the profound restorative phase of sleep, and that is where the exhaustion comes from. Those with the condition can sleep for extensive periods of time and still wake up feeling tired. A couple of sleep disorders associated with Fibromyalgia are Restless-Leg Syndrome and Sleep Apnea.

Experts have also come up with a theory of why those with Fibromyalgia feel pain. They believe those with the condition have a lower limit to pain because of heightened feelings in the brain to pain stimuli. They also believe that those with the condition have repetitive nerve stimulus that causes the brain to change. The brain simply overreacts to pain signs.

The intense, chronic pain and sensitivity in muscles and ligaments experienced by Fibromyalgia sufferers can be debilitating and persistent. Although more common in females, Fibromyalgia can happen to anyone and occur at any time. The largest obstacle with Fibromyalgia is that there is no known cure, which means a lifetime of pain relieving drugs, such as NSAIDS (Non-Steroidal Anti-Inflammatory Drugs) or other specialized medications. Such prescriptions can be expensive and have unpleasant side effects.

Other treatment options for Fibromyalgia include, hot and cold packs, stretching, regular exercise and ultrasound therapy. Therapeutic ultrasound for the treatment of fibromyalgia can provide deep tissue stimulation and pain relief. Ultrasound physical therapy can be a very effective way to manage the pain of Fibromyalgia.

Ultrasonic waves penetrate the skin to cause vibrations in tendons and soft tissues, providing gentle deep tissue heating that decreases pain and inflammation to speed healing. Ultrasound therapy increases blood flow and oxygen to tendons as well as relaxes muscles and decreases swelling. Ultrasound can be used as a pain therapy system to control Fibromyalgia pain flare-ups and can now be used in the comfort of your very own home.

Home ultrasound machines are now available for ultrasound Fibromyalgia treatments and rehabilitation. Visits to a chiropractor or physical therapist office for ultrasound physical therapy can be expensive and inconvenient, but it is now possible to rehab Fibromyalgia, and many other chronic injuries, in the comfort of your own home.

Because Fibromyalgia involves soft tissue inflammation, a specific kind of home ultrasound machine is required for treatment. A home ultrasound physical therapy machine should emit 1Mhz ultrasound waves. It is also vital to buy an FDA approved ultrasound unit that is quality manufactured. Your portable therapeutic ultrasound device should also be covered with at least a 1 year warranty.

Because these home ultrasound machines utilize pulsed ultrasound waves, they are very safe for use by the general public. Pulse ultrasound also is just as effective as continuous wave ultrasound that is used by doctors, but in home treatments will just be more often. With a portable therapeutic ultrasound machine, you can treat your bursitis daily when it is most convenient for you.

Reference: www.EZUltrasound.com

Introduction

Pain treatment is a multibillion dollar market that is saturated with a wide variety of branded and generic drugs. The NGF class has potential to be first of an entirely new type of painkiller to enter the sector in decades. Nevertheless, high expectations need to be tempered once the long term side effects, safety and pharmacoeconomics have been established.

Scope

*Overview of the current chronic pain market including epidemiology and key unmet needs.

*In depth analysis of the NGF class in development and proposed positioning in the treatment algorithm.

*Insights from interviews with five leading US and European key opinion leaders about the potential impact of NGF therapies.

*Identification of drivers and resistors to the commercial success of NGF therapies.

Highlights

Clinical studies have shown inhibition of nerve growth factor (NGF) has a strong analgesic effect. Three classifications block or sequester the NGF signal transduction pathway; NGF antagonists, tropomyosin-related kinase A inhibitors and NGF trap molecules. The most advanced pipeline candidate is Pfizer’s tanezumab with expected launch in 2012.

The safety of the NGF targeting therapies remains uncertain. Adverse effects shown in tanezumab trials indicate peripheral neuropathy, dysesthesia and paresthesia were the most frequent, but, no patient has taken tanezumab for longer than 6 months. Further long-term trials are required to establish the risk-benefit profile in chronic usage.

The involvement of Huge Pharma will aid the successful long-term commercialization of NGF therapies. Not only do these companies have the resources necessary to conduct the large long-term clinical trials required for chronic pain therapy, but their activity and experience in licensing pain products will encourage higher uptake upon launch.

Reasons to Buy

*Know the development of the NGF class and quantify pipeline.

*Identify where the NGF class will be positioned in the market as determined by interviewed key opinion leaders.

*Evaluation of the commercial considerations which will drive or inhibit the success and impact of the anti-NGFs.

Table of Contents :

“Overview 1
Catalyst 1
Summary 1
ABOUT  HEALTHCARE 2
About the central nervous system pharmaceutical analysis team 2
Executive Summary 3
Scope of the analysis 3
insight into the potential of nerve growth factor (NGF) for pain therapy 3
Related reports 5
Upcoming reports 5
Table of Contents 6
1. Pain – Market Potential 7
Key findings 7
Definition 8
Epidemiology 9
Chronic pain prevalence represents a substantial population 9
Back pain and arthritic conditions are the most prevalent chronic pain indications 12
Current treatment options 14
Management of chronic pain severity 16
Consequences of inadequately treated chronic pain 16
Current market overview 17
Unmet needs in pain management 18
Unmet need 1: improved efficacy in hard-to-treat pain conditions 19
Unmet need 2: abuse deterrent and abuse resistant approaches 20
Unmet need 3: safer pain management treatments 21
Unmet need 4: reduction in adverse effects 22
Target product profile versus current level of attainment 26
2. Class development 27
Key findings 27
Nerve growth factor has a key role in pain 28
Therapies targeting nerve growth factor (NGF) in pain 29
NGF antagonists 30
TrkA inhibitors 31
NGF trap molecules that compete with TrkA receptors 32
Pipeline overview 33
Strong presence of Huge Pharma in NGF pipeline 33
Key Nerve growth factor projects in development 34
Overview of NGF antagonists and Overview of TrkA inhibitors 34
Tanezumab (RN624; Pfizer) 35
Drug profile 35
Development overview 36
First Phase III studies to yield results in 2011 36
Promising Phase II data 38
Peripheral neuropathy and paresthesia documented in Phase II studies 41
Product positioning 41
Pfizer will obtain arthritis approval first 41
Tanezumab will be priced equivalent to existing biologics 42
SWOT analysis 43
REGN475 (SAR-164877, Sanofi-Aventis/Regeneron) 43
Drug profile 43
Development overview 44
JNJ-42160443 (formerly AMG403, Ortho-McNeil-Janssen Pharmaceuticals/Amgen) 45
Drug profile 45
Development overview 46
PG110 (hu-alphaD11, Abbott) 47
Drug profile 47
Development overview 48
Overview of TrkA inhibitors 48
BXL1H5 (huMNAC-13; BioXell/Cosmo Pharmaceutical SpA) 49
Drug profile 49
Development overview 50
3. Commercial considerations 51
Key findings 51
Key drivers to commercial success of the nerve growth factor (NGF) class 52
Driver 1: increased efficacy and long duration for NGF antagonists 52
Anti-NGF therapies exhibit stronger efficacy than NSAIDs 52
Long half-life represents more convenient dosing regimen 53
Driver 2: novel target in pain management 53
First novel class to enter pain management in decades 53
Validation of NGF pathway will increase development of small molecule inhibitors 54
Driver 3: strong investment in anti-NGF technologies 54
Entrance of Huge Pharma into the NGF pipeline will act as strong driver for R&D 54
Driver 4: limited abuse potential 55
Anti-NGF therapies offer no euphoric effects that could lead to misuse 55
Driver 5: innovation in technology 56
Improvement in monoclonal antibody technology will limit immunological response 56
Specificity of anti-NGF will limit adverse drug-drug interactions 56
Key resistors to commercial success of the nerve growth factor (NGF) class 57
Resistor 1: safety issues of chronic use unknown 57
Reproductive toxicology issues 57
Long-term safety profile unknown 58
Resistor 2: high pricing will affect reimbursement and positioning 59
NGF therapies will be priced at a premium 59
Insurance companies are likely to insist on last-line usage 60
Set up costs will limit coverage and increase costs 61
High price will restrict usage to last-line 62
Resistor 3: does not treat all pain indications 62
Efficacy is strong in inflammatory disorders compared to neuropathic indications 62
4. Case Study 64
Key findings 64
Will anti-NGFs mirror the impact of anti-TNFs? 65
Similar to anti-TNFs, anti-NGFs will become the first biological drugs in chronic pain 65
Unlike anti-TNF, anti-NGFs will remain the last-line therapeutic choice if cost remains high 66
Less unmet need in chronic pain will result in lower anti-NGF uptake 69
Anti-NGFs will be priced the same as anti-TNFs 71
Proof of concept will open doors to increased competition 71
Anti-NGF usage will also spread to other indications 72
Bibliography 74
Journals 74
Websites 77
reports 79
Presentations 79
Appendix A 80
Data definitions, limitations and assumptions 80
Standard units 80
Appendix B 81
Contributing experts 81
Report methodology 81
About82
About  Healthcare 82
About the Central Nervous System analysis team 83
Disclaimer 85

For more information please visit :

http://www.aarkstore.com/reports/Stakeholder-Opinions-Targeting-Nerve-Growth-Factor-for-Pain-Therapy-Groundbreaking-class-to-breathe-new-life-into-saturated-market-45178.html

Back pain is normally the most common condition that is consulted to doctors here and abroad. People who are prone to back pains are those individuals who constantly lifts weights and whose line of work requires heavy labor. It may be caused by a strained muscle, tussled nerve endings, strained ligaments and herniated discs. But remember that, through the  back pain therapy it is possible to treat back pain.

A lot of people believed that surgery is the only way to treat back pains effectively. But, small did they know that there are conservative methods that you can take advantage of. The pain can be alleviated through a simple and less expensive  back pain therapy.

Here are some of those back pain therapies:

physical therapy
enzyme therapy
spa therapy
Percutaneous Intramuscular Electrothermal therapy
Acupuncture
Yoga

Among all those back pain therapies, Yoga and physical therapy exercises can help a lot in managing back pain. Because it includes stretching and strength-building exercises. These exercises help strengthen and loosen not only your lower back but adjacent muscles like the legs, buttocks and abdomen as well. Developing the said areas makes a stabilizing support on your back. Stretching various muscles and ligaments during back exercises helps maintain and gain flexibility and mobility.

For stretching exercises you need to do the following:

1. Lie on the floor and let the vertebrae in your back to align themselves.

2. Hold the position for one minute.

3. Stretch you arms backwards and overhead and let your hands fall to the floor.

4. Relax and hold the position for one minute. Next, you need to pull one knee towards your chest while extending your other knee.

5. Hold your position then repeat it to your other knee.

6. Then pull both of your knees upwards and hold them near your chest area for a few seconds.

7. Drop your feet back and then keep repeating the movement.

8. Do the exercise on regular and prolonged periods of time for substantial results.

Strength-building exercises, on the other hand, helps build your lower back and adjacent muscles. To perform this, you have to lie on the floor with your knees bent and your lower back gently pressed on the floor. At times, this exercise relieves lower back pains immediately. The part within your lower and middle back is commonly vulnerable to pain. In strengthening this area, you need to prop your feet while lying down. Then lift your lower back and buttocks from the floor.

You may also do some hyper-extensions to your back. These are reverse sit-ups done while leaning on an exercise ball or on a Roman chair. Strength-building exercises should be done at least three times a week in consistent basis to attain improvements.

You could certainly do those exercises together with a physical therapist sessions, Because physical therapists are trained individuals that specialize on making physical regimens on pain areas and specific injuries and focuses on their healing. An accredited physical therapist helps you increase flexibility, motion range and blood flow better from what general exercise and stretching could offer.

Back pain may seem to be just a small problem for most people. But, there are some who have ignored the back pains that they have been experiencing – only to find out that it further lead into a worse case. If you want to find out more on back pains and the importance of making ways to relieve them, visit: – www.backpainmanagement.wordpress.com

Dental Pain Therapy Area Pipeline Report contains detailed information on the dental pain drug pipeline. This report provides insight into the pipeline status of dental pain drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

• Know a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
• Keep track of your competitors and partners by better understanding their product pipeline.
• Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
• Maintain a critical competitive advantage.

For more information, please visit :

http://www.aarkstore.com/reports/Dental-Pain-Therapy-Area-Pipeline-Report-14513.html

Or email us at press@aarkstore.com or call +919272852585

Muscle Pain Therapy Area Pipeline Report contains detailed information on the muscle pain drug pipeline. This report provides insight into the pipeline status of muscle pain drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

• Know a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
• Keep track of your competitors and partners by better understanding their product pipeline.
• Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
• Maintain a critical competitive advantage.

For more information, please visit :

http://www.aarkstore.com/reports/Muscle-Pain-Therapy-Area-Pipeline-Report-14629.html

Or email us at press@aarkstore.com or call +919272852585